Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta version (1.1 or 1.2) (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior to screening, migraine onset prior to age 50 and MONTHLY frequency of 4-14 MHD.~Exclusion Criteria:~* Are currently enrolled in or have participated within the last 30 days or within 5 half-lives (whichever is longer) in a clinical trial involving an investigational product.~* Current use or prior exposure to galcanezumab or another Calcitonin Gene-Related Peptide (CGRP) antibody.~* Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins, or to galcanezumab.~* History of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Galcanezumab 120mg (Type: EXPERIMENTAL): Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.
- Galcanezumab 240mg (Type: EXPERIMENTAL): Galcanezumab 240mg given by SC injection once a month for 6 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo given by SC injection once a month for 6 months.
- Galcanezumab 120mg Maximum Extended Enrollment Cohort (Type: EXPERIMENTAL): Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.
- Galcanezumab 240mg Maximum Extended Enrollment Cohort (Type: EXPERIMENTAL): Galcanezumab 240mg given by SC injection once a month for 6 months.
- Placebo Maximum Extended Enrollment Cohort (Type: PLACEBO_COMPARATOR): Placebo given by SC injection once a month for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).